Last reviewed · How we verify

Everolimus+Tacrolimus+Prednisone — Competitive Intelligence Brief

Everolimus+Tacrolimus+Prednisone (Everolimus+Tacrolimus+Prednisone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy. Area: Immunology / Transplantation.

marketed Immunosuppressive combination therapy mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Everolimus+Tacrolimus+Prednisone (Everolimus+Tacrolimus+Prednisone) — Fundação Pró Rim. This triple immunosuppressive regimen inhibits T-cell proliferation and activation to prevent organ rejection after transplantation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Everolimus+Tacrolimus+Prednisone TARGET Everolimus+Tacrolimus+Prednisone Fundação Pró Rim marketed Immunosuppressive combination therapy mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone)
ATG+mycophénolate mofétil+tacrolimus ATG+mycophénolate mofétil+tacrolimus University Hospital, Toulouse marketed Immunosuppressive combination therapy T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
Basiliximab, Tacrolimus, MMF Basiliximab, Tacrolimus, MMF University Hospital Freiburg marketed Immunosuppressive combination therapy IL-2 receptor (basiliximab); calcineurin (tacrolimus); IMPDH (MMF)
CsA+Rapamune+CS CsA+Rapamune+CS Pfizer marketed Immunosuppressive combination therapy Calcineurin, mTOR, glucocorticoid receptor
CsA+MMF+CS CsA+MMF+CS Pfizer marketed Immunosuppressive combination therapy Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS)
ATG/PTCy ATG/PTCy Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine marketed Immunosuppressive combination therapy
Mycophenolate+Tacrolimus+Prednisone Mycophenolate+Tacrolimus+Prednisone Fundação Pró Rim marketed Immunosuppressive combination therapy T-cell proliferation and activation (multiple targets: IMPDH, calcineurin, glucocorticoid receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy class)

  1. University Hospital, Brest · 2 drugs in this class
  2. Pfizer · 2 drugs in this class
  3. Fundação Pró Rim · 2 drugs in this class
  4. Haukeland University Hospital · 1 drug in this class
  5. Imperial College Healthcare NHS Trust · 1 drug in this class
  6. Jinnah Postgraduate Medical Centre · 1 drug in this class
  7. Novartis · 1 drug in this class
  8. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
  9. Swiss Cancer Institute · 1 drug in this class
  10. University Hospital Freiburg · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Everolimus+Tacrolimus+Prednisone — Competitive Intelligence Brief. https://druglandscape.com/ci/everolimus-tacrolimus-prednisone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: